| Literature DB >> 31671076 |
Josine M de Winter1, Joery P Molenaar2,3, Michaela Yuen1,4, Robbert van der Pijl1,5, Shengyi Shen5, Stefan Conijn1, Martijn van de Locht1, Menne Willigenburg1, Sylvia Jp Bogaards1, Esmee Sb van Kleef2, Saskia Lassche2, Malin Persson6,7, Dilson E Rassier6, Tamar E Sztal8, Avnika A Ruparelia8, Viola Oorschot9, Georg Ramm9,10, Thomas E Hall11, Zherui Xiong11, Christopher N Johnson12, Frank Li5, Balazs Kiss5, Noelia Lozano-Vidal1, Reinier A Boon1, Manuela Marabita13, Leonardo Nogara13, Bert Blaauw13, Richard J Rodenburg14, Benno Küsters15, Jonne Doorduin2, Alan H Beggs16, Henk Granzier5, Ken Campbell17, Weikang Ma18, Thomas Irving18, Edoardo Malfatti19, Norma B Romero20,21, Robert J Bryson-Richardson7, Baziel Gm van Engelen2, Nicol C Voermans2, Coen Ac Ottenheijm1,5.
Abstract
The mechanisms that modulate the kinetics of muscle relaxation are critically important for muscle function. A prime example of the impact of impaired relaxation kinetics is nemaline myopathy caused by mutations in KBTBD13 (NEM6). In addition to weakness, NEM6 patients have slow muscle relaxation, compromising contractility and daily life activities. The role of KBTBD13 in muscle is unknown, and the pathomechanism underlying NEM6 is undetermined. A combination of transcranial magnetic stimulation-induced muscle relaxation, muscle fiber- and sarcomere-contractility assays, low-angle x-ray diffraction, and superresolution microscopy revealed that the impaired muscle-relaxation kinetics in NEM6 patients are caused by structural changes in the thin filament, a sarcomeric microstructure. Using homology modeling and binding and contractility assays with recombinant KBTBD13, Kbtbd13-knockout and Kbtbd13R408C-knockin mouse models, and a GFP-labeled Kbtbd13-transgenic zebrafish model, we discovered that KBTBD13 binds to actin - a major constituent of the thin filament - and that mutations in KBTBD13 cause structural changes impairing muscle-relaxation kinetics. We propose that this actin-based impaired relaxation is central to NEM6 pathology.Entities:
Keywords: Genetic diseases; Muscle Biology; Neuromuscular disease; Skeletal muscle
Mesh:
Substances:
Year: 2020 PMID: 31671076 PMCID: PMC6994151 DOI: 10.1172/JCI124000
Source DB: PubMed Journal: J Clin Invest ISSN: 0021-9738 Impact factor: 14.808